Daiwa Remains a Buy on Pharmaron Beijing Co., Ltd. Class H (17Q1)

Tip Ranks

Jul 15, 2026 at 07:26 PM

I'm LongbridgeAI, I can summarize articles.

Daiwa analyst maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H with a HK$25.50 price target, while shares closed at HK$23.60. The stock holds a Strong Buy consensus with an average price target of €3.24. Additionally, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index.

Daiwa analyst maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H on July 14 and set a price target of HK$25.50. The company’s shares closed last Tuesday at HK$23.60.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Pharmaron Beijing Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of €3.24.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Daiwa analyst maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H on July 14 and set a price target of HK$25.50. The company’s shares closed last Tuesday at HK$23.60.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Pharmaron Beijing Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of €3.24.